Frontier
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2021; 27(41): 7014-7024
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7014
Recent insights into the characteristics and role of peritoneal macrophages from ascites of cirrhotic patients
Pilar García-Peñarrubia, Antonio José Ruiz-Alcaraz, Miriam Ruiz-Ballester, Tamara Nadira Ramírez-Pávez, María Martínez-Esparza
Pilar García-Peñarrubia, Antonio José Ruiz-Alcaraz, Miriam Ruiz-Ballester, Tamara Nadira Ramírez-Pávez, María Martínez-Esparza, Department of Biochemistry and Molecular Biology B and Immunology, School of Medicine, University of Murcia, Murcia 30100, Spain
Author contributions: García-Peñarrubia P designed the overall concept outline of this manuscript and was responsible for writing, editing, reviewing the bibliography and approving the final version of the article; Ruiz-Alcaraz AJ wrote the manuscript, compiled, reviewed and edited the bibliography, adapted the figures and approved the final version of the article; Martínez-Esparza M wrote the manuscript, compiled and reviewed the bibliography and approved the final version of the article; Ruiz-Ballester M and Ramírez-Pávez TN meet the criteria for authorship established by the International Committee of Medical Journal Editors and approved the final version of the article.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Pilar García-Peñarrubia, MD, PhD, Full Professor, Senior Researcher, Department of Biochemistry and Molecular Biology B and Immunology, School of Medicine, University of Murcia, Campus de Espinardo, Murcia 30100, Spain. pigarcia@um.es
Received: April 14, 2021
Peer-review started: April 14, 2021
First decision: June 23, 2021
Revised: July 2, 2021
Accepted: October 11, 2021
Article in press: October 11, 2021
Published online: November 7, 2021
Abstract

Macrophages are a diverse myeloid cell population involved in innate and adaptive immune responses, embryonic development, wound repair, and regulation of tissue homeostasis. These cells link the innate and adaptive immunities and are crucial in the development and sustainment of various inflammatory diseases. Macrophages are tissue-resident cells in steady-state conditions; however, they are also recruited from blood monocytes after local pathogen invasion or tissue injury. Peritoneal macrophages vary based on their cell complexity, phenotype, and functional capabilities. These cells regulate inflammation and control bacterial infections in the ascites of decompensated cirrhotic patients. Our recent work reported several phenotypic and functional characteristics of these cells under both healthy and pathological conditions. A direct association between cell size, CD14/CD16 expression, intracellular level of GATA-6, and expression of CD206 and HLA-DR activation/maturation markers, indicate that the large peritoneal macrophage CD14highCD16high subset constitutes the mature phenotype of human resident peritoneal macrophages during homeostasis. Moreover, elevated expression of CD14/CD16 is related to the phagocytic capacity. The novel large CD14highCD16high peritoneal subpopulation is increased in the ascites of cirrhotic patients and is highly sensitive to lipopolysaccharide (LPS)-induced activation, thereby exhibiting features of inflammatory priming. Thus, phosphorylation of ERK1/2, PKB/Akt, and c-Jun is remarkably increased in response to LPS in vitro, whereas that of p38 MAPK is reduced compared with the monocyte-derived macrophages from the blood of healthy controls. Furthermore, in vitro activated monocyte-derived macrophages from ascites of cirrhotic patients secreted significantly higher levels of IL-6, IL-10, and TNF-α and lower amounts of IL-1β and IL-12 than the corresponding cells from healthy donor’s blood. Based on these results, other authors have recently reported that the surface expression level of CD206 can be used to identify mature, resident, inflammatory peritoneal macrophages in patients with cirrhosis. Soluble CD206 is released from activated large peritoneal macrophages, and increased concentrations in patients with cirrhosis and spontaneous bacterial peritonitis (SBP) indicate reduced odds of survival for 90 d. Hence, the level of soluble CD206 in ascites might be used to identify patients with SBP at risk of death. In conclusion, peritoneal macrophages present in ascites of cirrhotic patients display multiple phenotypic modifications characterized by reduced ratio of cells expressing several membrane markers, together with an increase in the ratios of complex and intermediate subpopulations and a decrease in the classic-like subset. These modifications may lead to the identification of novel pharmaceutical targets for prevention and treatment of hepatic damage.

Keywords: Cirrhosis, Inflammation, Peritoneal macrophages, Phenotypic markers, Activation routes

Core Tip: This frontier article is based on a summary of recent relevant publications on the biology of mouse, as the main animal model used, and human peritoneal macrophages under the perspective of its future clinical translation to the role that these cells can play on several human liver diseases. Concretely, we have reviewed recent findings on several characteristics of human peritoneal macrophages obtained from the ascites of cirrhotic patients compared with those obtained from healthy donors. Featured article: Role of MAP kinases and PI3K-Akt on the cytokine inflammatory profile of peritoneal macrophages from the ascites of cirrhotic patients.